Mitchell Chan - SEC Form 4 Insider Trading Activity
Summary
Updated Aug 4, 2026
Mitchell Chan has filed 1 SEC Form 4 filing across 1 company in the last 90 days - selling. Lifetime open-market sales: $72K.
Profile
Mitchell Chan is a corporate insider at Avalo Therapeutics, Inc. (AVTX). Chan has also held reporting roles at REGENXBIO Inc. (RGNX). Chan has reported 3 insider filings with the SEC since 2025. The most recent filing was in May 2026.
| Role | Insider |
|---|---|
| Notability | 20/100 |
Board memberships
- Avalo Therapeutics, Inc.
- REGENXBIO Inc.
Trading Pattern
InsiderAlpha's records for Mitchell Chan go back to 2025: 3 primary Form 4 filings, an average of 1.5 per year. 1 recorded transaction carries a Rule 10b5-1 flag, meaning it was pre-scheduled under a written trading plan rather than discretionary.
Career & Filing History
Every role Mitchell Chan has reported on a Form 4, reconstructed from the filings themselves - reporting insiders must state their relationship to the issuer (officer title, director seat, or 10% ownership) on every filing.
- Insider at Avalo Therapeutics, Inc. (AVTX) - 2 filings, 2026
- Chief Financial Officer at REGENXBIO Inc. (RGNX) - 1 filing, 2025
Recent Transactions
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-05-07 | AVTX | Avalo Therapeutics, Inc. | S - Open-market sale [10b5-1] | 3.2K | $22.88 | $72K |
| 2026-03-31 | AVTX | Avalo Therapeutics, Inc. | M - Option exercise | 3.2K | - | |
| 2025-09-01 | RGNX | REGENXBIO Inc. | F - Tax withholding / forfeiture | 4.9K | $8.93 | $44K |
Companies - Last 90 Days
- Avalo Therapeutics, Inc. (AVTX) - 1 filing, last 2026-05-07
Other Insiders Active in the Same Stocks
Insiders who reported open-market trades at the companies Mitchell Chan has recently filed at. Multiple unrelated insiders buying the same stock within a short window - cluster buying - has historically been one of the strongest Form 4 signals.
- Mittie Doyle - $2.93M of AVTX open-market activity in the last 12 months
- Christopher Ryan Sullivan - $1.89M of AVTX open-market activity in the last 12 months
- Paul Varki - $1.51M of AVTX open-market activity in the last 12 months
- Jonathan Goldman - $163K of AVTX open-market activity in the last 12 months
More Notable Insiders
Other corporate insiders with significant SEC Form 4 track records on InsiderAlpha:
- Shankh Mitra
- MITSUI SUMITOMO INSURANCE CO LTD
- Arturo R. Moreno
- Matthew T. Moroun
- Dustin A. Moskovitz
- MPM BIOVENTURES 2018, L.P.
- MSD CAPITAL, L.P.
- Mubadala Investment Co PJSC
Frequently Asked Questions
Who is Mitchell Chan?
Mitchell Chan is a corporate insider at Avalo Therapeutics, Inc. (AVTX). Chan has also held reporting roles at REGENXBIO Inc. (RGNX). Chan has reported 3 insider filings with the SEC since 2025. The most recent filing was in May 2026.…
How many SEC Form 4 filings has Mitchell Chan submitted recently?
1 primary Form 4 filing in the last 90 days, covering 1 company.
Has Mitchell Chan been buying or selling stock?
Recorded transactions: 0 open-market purchases and 1 open-market sale ($72K) across all tracked filings.
Where can I see all of Mitchell Chan's SEC filings?
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Learn More
Open the live Mitchell Chan profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.